Mirum Pharmaceuticals Management
Management criteria checks 3/4
Mirum Pharmaceuticals' CEO is Chris Peetz, appointed in Mar 2019, has a tenure of 5.25 years. total yearly compensation is $6.45M, comprised of 10.2% salary and 89.8% bonuses, including company stock and options. directly owns 0.54% of the company’s shares, worth $7.45M. The average tenure of the management team and the board of directors is 3.3 years and 3.9 years respectively.
Key information
Chris Peetz
Chief executive officer
US$6.5m
Total compensation
| CEO salary percentage | 10.2% |
| CEO tenure | 5.3yrs |
| CEO ownership | 0.5% |
| Management average tenure | 3.3yrs |
| Board average tenure | 3.9yrs |
Recent management updates
Recent updates
Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Business And Shares Still Trailing The Industry
May 28
Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Value
Apr 22Mirum Pharmaceuticals: Advancing On Several Key Fronts
Mar 05There's Reason For Concern Over Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Price
Dec 26What Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) P/S Is Not Telling You
Jun 10Industry Analysts Just Made A Captivating Upgrade To Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Revenue Forecasts
Apr 18Mirum's liver disease drug Livmarli gets EMA committee nod for approval in EU
Oct 14Mirum: Great Sales Start For Livmarli Paves The Way For Long-Term Growth
Aug 17Mirum Pharmaceuticals announces $80M stock offering
Aug 09Mirum Pharmaceuticals: Post-Approval Execution Looks Excellent
May 27Is Mirum Pharmaceuticals (NASDAQ:MIRM) In A Good Position To Invest In Growth?
Apr 22Mirum Pharmaceuticals Gets The 'Thumbs Up'
Dec 16CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$159m |
| Dec 31 2023 | US$6m | US$660k | -US$163m |
| Sep 30 2023 | n/a | n/a | -US$164m |
| Jun 30 2023 | n/a | n/a | -US$176m |
| Mar 31 2023 | n/a | n/a | -US$129m |
| Dec 31 2022 | US$4m | US$624k | -US$136m |
| Sep 30 2022 | n/a | n/a | -US$42m |
| Jun 30 2022 | n/a | n/a | -US$53m |
| Mar 31 2022 | n/a | n/a | -US$70m |
| Dec 31 2021 | US$4m | US$600k | -US$84m |
| Sep 30 2021 | n/a | n/a | -US$179m |
| Jun 30 2021 | n/a | n/a | -US$153m |
| Mar 31 2021 | n/a | n/a | -US$132m |
| Dec 31 2020 | US$3m | US$512k | -US$103m |
| Sep 30 2020 | n/a | n/a | -US$84m |
| Jun 30 2020 | n/a | n/a | -US$78m |
| Mar 31 2020 | n/a | n/a | -US$68m |
| Dec 31 2019 | US$6m | US$458k | -US$53m |
| Sep 30 2019 | n/a | n/a | -US$61m |
| Dec 31 2018 | US$385k | US$32k | -US$26m |
Compensation vs Market: Chris's total compensation ($USD6.45M) is about average for companies of similar size in the US market ($USD5.67M).
Compensation vs Earnings: Chris's compensation has increased whilst the company is unprofitable.
CEO
Chris Peetz (45 yo)
5.3yrs
Tenure
US$6,451,720
Compensation
Mr. Christopher Peetz, also known as Chris, serves as Entrepreneur-in-Residence at Frazier Management, L.L.C since May 30, 2017. He also serves as Entrepreneur-in-Residence at Frazier Life Sciences Managem...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 5.3yrs | US$6.45m | 0.54% $ 7.4m | |
| COO & President | 4.2yrs | US$2.37m | 0.042% $ 585.2k | |
| Chief Financial Officer | less than a year | US$4.69m | 0.031% $ 423.2k | |
| Chief Scientific Officer | less than a year | US$1.51m | 0.20% $ 2.7m | |
| Vice President of Investor Relations and Finance | no data | no data | no data | |
| Chief Compliance Officer | 4.2yrs | no data | no data | |
| Senior Vice President of Human Resources | 5.4yrs | no data | no data | |
| Chief Development Officer | 5.5yrs | US$1.51m | 0.20% $ 2.8m | |
| Senior vice President of Quality | 2.4yrs | no data | no data | |
| Senior Vice President of Technical Operations | 1.4yrs | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data | |
| Senior VP & Global Controller | no data | no data | 0.0037% $ 51.4k |
3.3yrs
Average Tenure
54yo
Average Age
Experienced Management: MIRM's management team is considered experienced (3.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | no data | US$6.45m | 0.54% $ 7.4m | |
| Independent Director | 5.6yrs | US$401.75k | 0% $ 0 | |
| Independent Director | 4.9yrs | US$426.75k | 0.021% $ 292.5k | |
| Independent Non-Executive Chairman of the Board | 5.3yrs | US$451.75k | 0.81% $ 11.2m | |
| Independent Director | 5yrs | US$421.75k | 0.014% $ 197.4k | |
| Independent Director | 1.2yrs | US$671.53k | 0% $ 0 | |
| Independent Director | 2.8yrs | US$411.75k | 0% $ 0 | |
| Independent Director | 1.6yrs | US$194.47k | 0% $ 0 | |
| Independent Director | 2yrs | US$411.75k | 0% $ 0 |
3.9yrs
Average Tenure
58yo
Average Age
Experienced Board: MIRM's board of directors are considered experienced (3.9 years average tenure).